Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07809321
Enrolling by invitation Not applicable

Beta-Alanine Effects on Neuromuscular and Cardiovascular Performance in Female Rugby Players

NCT07809321 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-09-09

Condition(s) studied

Beta Alanine SupplementationPlacebo - Control

Investigational drug(s) / intervention(s)

Placebo ComparatorBeta-Alanine

Placebo Comparator: Placebo group will receive 4.8 grams per day of placebo, containing fructose (3000 mg) and excipients (1800 mg) such as cellulose, calcium phosphate, silicon dioxide, and magnesium stearate. Both supplements will be matched in appearance and dosing schedule to ensure proper blinding. Compliance with the supplementation protocol will be monitored throughout the intervention period.

Beta-Alanine: Participants assigned to the experimental group will receive beta-alanine supplementation (CROWN Sport Nutrition, La Rioja, España) at a dose of 4.8 grams per day for a period of four weeks . The supplement will be administered in divided doses throughout the day to enhance absorption and minimize potential side effects such as paresthesia

Study summary

This study will examine the effects of beta-alanine supplementation on physical performance in female rugby players, who will ingest 4.8 grams/day over a four-week period. The research will evaluate both cardiovascular and neuromuscular outcomes, with cardiovascular performance assessed using the Bronco Test (a field-based measure of endurance and repeated high-intensity running ability) and neuromuscular performance (e.g.vertical jump capacity).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Rugby participants with at least three years of professional experience. Exclusion Criteria: * Suffering from any chronic pathology or an injury in the month prior to the investigation. * Intolerance to beta-alanine supplementation * Participants aged outside the range of 18 to 40 years.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Álvaro López Samanes Madrid Madrid

More Universidad Pontificia Comillas trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07809321 on ClinicalTrials.gov ↗ ← All trials in Spain